gunsnkars, SOS habitually does not carefully review his articles before releasing them (last patient enrolled 11/14). Also while his trial prognosis is correct (IMHO) he missed important released information; NWBO does not have to worry about a three year survival rate of 25% as the blended survival rate at about 38 months is 30%. The only important contribution in this article is his logical speculation that in assessing immunotherapy trials the FDA will put the emphasis on positive long term PFS and especially OS results. This will give this P3 trial a significant edge (JMHO).
Market Data 
Markets 
AI
